Zdravsiti

History

2024: Appointment of Yevgeny Oruzheinikov as CEO

In June 2024, it became known about the appointment of Yevgeny Ruzheinikov as the new general director of the pharmaceutical marketplace Zdravsiti"" (part of the "" group Leaked). He replaced, Boris Popov who moved to the chain of pharmacies "" Rigla(also part of the Protek Group of Companies) and headed it. The change of the head of Zdravsiti is evidenced by the data of the service Contour Focus"," which Zdrav.Expert got acquainted with. More. here

2023: Data breach of millions of customers

On February 2, 2023, it became known about the leakage of data from users of the Zdravsiti Internet pharmacy. According to the Telegram channel "Information Leaks," the database put up for sale on the shadow forum contains more than 8.9 million unique phone numbers and almost 3.4 million unique email addresses.

Representatives of the Telegram channel said that they selectively checked the records from the posted archive, and noted that it indicated the information of real people.

Data of millions of customers of Zdravsiti pharmacy was leaked

At the same time, the head of the Zdravsiti marketplace, Dauren Abeuov, in a conversation with TASS, said that the information about the leakage of the service's customer database was not true. According to him, the first results of the audit show that the database is irrelevant.

Information about the hacking of the online service "Zdravsiti" is not true. We are currently conducting a thorough investigation into the incident. The first conclusions indicate that the information that appeared is provocative. From the trial lines of the upload, given as an example of confirmation, it is definitely clear that the base is irrelevant, "Abeuov said.

On the hotline of the Internet pharmacy itself, Zdravsiti reports that they do not know anything about the leakage of a giant array of data.

There was no information about the leak. You shouldn't worry, "said a representative of the pharmacy chain to the Podyem publication.

The Zdravsiti service allows you to make online orders for the delivery of medicines, medical devices, hygiene products, dietary supplements, cosmetics and other health and beauty products. The marketplace operates 81 regions of Russia (as of the beginning of February 2023).^[1]

2022: Atlas Investments CEO's exit from capital

In December 2022, it became known about the change of co-owners of the Zdravsiti online pharmacy. According to the SPARK-Interfax system, Andrei Perfiliev, general director of Atlas Investments, transferred to the Protek group (one of the largest pharmaceutical distributors in the Russian Federation). We are talking about 3%.

As a result of the conclusion of the transaction, the shares of Zdravsiti LLC by December 9, 2022 were distributed as follows: 94% belongs to Protek CV, 3% to Protek PJSC and another 3% to Sergei Musienko, a former co-owner of Atlas structures and CEO of several software companies.

Atlas Investments CEO withdraws from Zdravsiti capital

Earlier in 2022, Atlas Investments went out of the Medicats business, which developed a platform for providing electronic prescriptions for the implementation of a project for the remote sale of prescription drugs.

Atlas Investments is associated with Protek Group of Companies, which includes the pharmaceutical distributor of the same name and the Rigla pharmacy chain. The company belongs to Andrei Perfiliev, the ex-general director of the Atlas clinic, bought by Protec in 2020.

The reason for the exit of the Protek structure from the Medicata business could be the service's failure to fulfill the covenants reached during the conclusion of transactions, one of the sources from among the top managers of the pharmaceutical market told Kommersant. For Medicata, he said, cooperation with Protec was important because of access to the ecosystem built by the group, which includes clinics and pharmacy chains.

The electronic prescription system does not have a source of funding by 2022, says DSM Group CEO Sergei Shulyak. Players in this market planned to charge pharmacies, but so far this process is delayed, he explains. In addition, the expert explains, the regions require the integration of electronic prescriptions with a single medical information and analytical system at the expense of companies. This means, Mr. Shulyak believes, that operators are forced to spend their funds at a stage when they are not yet receiving income.^[2]

Notes